Skip to main content

Approach to pulmonary hypertension

Current Rheumatology Reports volume 2, pages 517–523 (2000)Cite this article

Abstract

Until recently, many physicians considered pulmonary hypertension a rare and esoteric condition that is difficult to diagnose and nearly impossible to treat. However, pulmonary hypertension can complicate a variety of relatively common diseases and, with the development of new and effective therapies, there is a need for greater awareness of this condition. Pulmonary hypertension should be considered when patients present with unexplained shortness of breath, chest pain, or syncope. The usual delay of 1 to 2 years between onset of symptoms and diagnosis underscores the importance of considering pulmonary hypertension in the differential diagnosis of patients who present with atypical cardiorespiratory symptoms.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. Nootens MT, Berarducci LA, Kaufmann E, et al.: The prevalence and significance of a patent foramen ovale in pulmonary hypertension. Chest 1993, 104:1673–1675.

    PubMed  CAS  Google Scholar 

  2. Sanner BM, Doberauer C, Konermann M, et al.: Pulmonary Hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med 1997, 157:2483–2487.

    PubMed  Article  CAS  Google Scholar 

  3. Kessler R, Chaouat A, Weitzenblum E, et al.: Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J 1996, 9:787–794.

    PubMed  Article  CAS  Google Scholar 

  4. D’Alonzo GE, Barst RJ, Ayres SM, et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343–349.

    PubMed  CAS  Google Scholar 

  5. Bernstein RJ, Ford RL, Clausen JL, Moser KM: Membrane diffusion and capillary blood volume in chronic thromboembolic pulmonary hypertension. Chest 1996, 110:1430–1436.

    PubMed  CAS  Google Scholar 

  6. Palmer SM, Robinson LJ, Wang A, et al.: Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998, 113:237–240. interest to clinicians.

    PubMed  CAS  Google Scholar 

  7. Humbert M, Maitre S, Capron F, et al.: Pulmonary edema complicating continuous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998, 157:1681–1685.

    PubMed  CAS  Google Scholar 

  8. Dufour B, Maitre S, Humbert M, et al.: High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary veno-occlusive diseases. AJR Am J Roentgenol 1998, 171:1321–1324.

    PubMed  CAS  Google Scholar 

  9. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76–81.

    PubMed  CAS  Article  Google Scholar 

  10. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996, 334:296–302.

    PubMed  Article  CAS  Google Scholar 

  11. Nootens M, Schrader B, Kaufmann E, et al.: Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995, 107:54–57.

    PubMed  CAS  Google Scholar 

  12. Raffy O, Azarian R, Brenot F, et al.: Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996, 93:484–488.

    PubMed  CAS  Google Scholar 

  13. Sitbon O, Brenot F, Denjean A, et al.: Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995, 151:384–389.

    PubMed  CAS  Google Scholar 

  14. McLaughlin VV, Genthner DE, Panella MM, et al.: Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999, 130:740–743. ful study.

    PubMed  CAS  Google Scholar 

  15. Kuo PC, Plotkin JS, Gaine S, et al.: Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999, 67:1087–1093. interest to clinicians.

    PubMed  Article  CAS  Google Scholar 

  16. Sandoval J, Gaspar J, Pulido T, et al.: Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998, 32:297–304.

    PubMed  Article  CAS  Google Scholar 

  17. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP: Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996, 15:100–105.

    PubMed  CAS  Google Scholar 

  18. Katz DS, Scalzetti EM, Katzenstein AL, Kohman LJ: Pulmonary veno-occlusive disease presenting with thrombosis of pulmonary arteries. Thorax 1995, 50:699–700.

    PubMed  CAS  Article  Google Scholar 

  19. Moser KM, Fedullo PF, Finkbeiner WE, Golden J: Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation 1995, 91:741–745.

    PubMed  CAS  Google Scholar 

  20. Jamieson SW, Auger WR, Fedullo PF, et al.: Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg 1993, 106:116–126.

    PubMed  CAS  Google Scholar 

  21. Hassell KL: Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998, 9:107–117.

    PubMed  CAS  Google Scholar 

  22. Voelkel NF, Tuder RM: Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995, 8:2129–2138.

    PubMed  Article  CAS  Google Scholar 

  23. Frank H, Mlczoch J, Huber K, et al.: The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997, 112:714–721.

    PubMed  CAS  Google Scholar 

  24. Higenbottam T, Cremona G: Acute and chronic hypoxic pulmonary hypertension. Eur Respir J 1993, 6:1207–1212.

    PubMed  CAS  Google Scholar 

  25. Weiss BM, Zemp L, Seifert B, Hess OM: Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998, 31:1650–1657.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Pulmonary and Critical Care Medicine, University of California, San Diego School of Medicine, La Jolla, CA, USA

    Gordon L. Yung MD & Lewis J. Rubin MD

Authors
  1. Gordon L. Yung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lewis J. Rubin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yung, G.L., Rubin, L.J. Approach to pulmonary hypertension. Curr Rheumatol Rep 2, 517–523 (2000). https://doi.org/10.1007/s11926-000-0030-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-000-0030-x

Keywords

  • Pulmonary Hypertension
  • Idiopathic Pulmonary Fibrosis
  • Epoprostenol
  • Primary Pulmonary Hypertension
  • Pulmonary Hypertensive Patient